|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:2020
gptkb:FDA
|
|
gptkbp:clinical_trial
|
Phase 3
RADIANCE
SUNBEAM
|
|
gptkbp:contraindication
|
pregnancy
active infection
liver impairment
|
|
gptkbp:dosage_form
|
gptkb:capsule
|
|
gptkbp:drug_interactions
|
immunosuppressants
CYP3 A4 inducers
CYP2 C8 inhibitors
|
|
gptkbp:formulation
|
delayed-release
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zeposia
|
|
gptkbp:ingredients
|
ozanimod
|
|
gptkbp:invention
|
2028
|
|
gptkbp:manufacturer
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:marketed_as
|
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
sphingosine 1-phosphate receptor modulator
|
|
gptkbp:patient_population
|
adults
pediatric patients
|
|
gptkbp:pharmacokinetics
|
distribution
metabolism
absorption
excretion
|
|
gptkbp:regulatory_compliance
|
prescription only
|
|
gptkbp:research_focus
|
safety profile
long-term efficacy
comparative effectiveness
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety_measures
|
heart rate monitoring
liver function tests
blood pressure monitoring
|
|
gptkbp:side_effect
|
gptkb:disease
headache
hypertension
visual disturbances
bradycardia
pulmonary complications
elevated liver enzymes
gastrointestinal symptoms
|
|
gptkbp:storage
|
room temperature
protected from light
protected from moisture
|
|
gptkbp:strength
|
0.92 mg
|
|
gptkbp:trade
|
gptkb:Zeposia
|
|
gptkbp:type_of_care
|
once daily dosing
|
|
gptkbp:used_for
|
gptkb:multiple_sclerosis
|
|
gptkbp:bfsParent
|
gptkb:Bristol-Myers
|
|
gptkbp:bfsLayer
|
7
|